TY - JOUR
T1 - Dynamics of raltegravir resistance profile in an HIV type 2-infected patient
AU - Xu, Li
AU - Anderson, Jane
AU - Garrett, Nigel
AU - Ferns, Bridget
AU - Wildfire, Adrian
AU - Cook, Pamela
AU - Workman, Judith
AU - Graham, Susan
AU - Smit, Erasmus
PY - 2009/8/1
Y1 - 2009/8/1
N2 - The evolutionary dynamics of RAL resistance in the HIV-2 virus were examined through population and clonal sequence analysis of the IN from baseline, during treatment, and after stopping RAL therapy. The treatment failure of an RAL regimen in the HIV-2 patient studied was associated with the emergence of mutations via the N155H resistance pathway and subsequent switching to the Y143C mutational route. This study has also identified four novel secondary mutations, Q91R, S147G, A153G, and M183I, not previously reported in HIV-1 patients failing RAL therapy. Resistant variants involving the Y143C pathway were noted to have persisted beyond 4 weeks following the cessation of RAL therapy. All resistance-associated mutations were lost at 20 weeks after stopping RAL therapy. Our findings provide evidence supporting the supposition that substantial cross-resistance between strand transfer IN-Is is likely in HIV-2 as shown in HIV-1.
AB - The evolutionary dynamics of RAL resistance in the HIV-2 virus were examined through population and clonal sequence analysis of the IN from baseline, during treatment, and after stopping RAL therapy. The treatment failure of an RAL regimen in the HIV-2 patient studied was associated with the emergence of mutations via the N155H resistance pathway and subsequent switching to the Y143C mutational route. This study has also identified four novel secondary mutations, Q91R, S147G, A153G, and M183I, not previously reported in HIV-1 patients failing RAL therapy. Resistant variants involving the Y143C pathway were noted to have persisted beyond 4 weeks following the cessation of RAL therapy. All resistance-associated mutations were lost at 20 weeks after stopping RAL therapy. Our findings provide evidence supporting the supposition that substantial cross-resistance between strand transfer IN-Is is likely in HIV-2 as shown in HIV-1.
UR - http://www.scopus.com/inward/record.url?scp=70349221276&partnerID=8YFLogxK
U2 - 10.1089/aid.2009.0039
DO - 10.1089/aid.2009.0039
M3 - Article
C2 - 19618998
AN - SCOPUS:70349221276
SN - 0889-2229
VL - 25
SP - 843
EP - 847
JO - AIDS Research and Human Retroviruses
JF - AIDS Research and Human Retroviruses
IS - 8
ER -